Apo-Abacavir-Lamivudine-Zidovudine · DIN 02416255 · 300 mg & 150 mg & 300 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued April 17, 2025 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apo-Abacavir-Lamivudine-Zidovudine · DIN 02416255
Manufacturer: Apotex Inc.; listing date 2016-01-28
Health Canada: Cancelled post market since 2025-04-17 · brand APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE · ATC J05AR04 ZIDOVUDINE, LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 300 MG, LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Apotex inc · schedule Prescription
Apo-Abacavir-Lamivudine-Zidovudine: Formulary list price $13.64 per unit (the source does not state the unit; exact figure $13.6425). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416255)
Source record
DIN 02416255: Apo-Abacavir-Lamivudine-Zidovudine
Raw flags: sec3=Y
Item: 081800065; group id 59; item number 0118; lccId None; manufacturer id APX
Source form: Tab; strength: 300mg & 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $13.6425; ministry $13.6425
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416255
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90068
Interchangeable products
Trizivir · DIN 02244757 · $13.6425
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since April 17, 2025 — choose a marketed DIN from the same-category list.